旅行者腹泻:临床回顾。

IF 4.2 Q3 Pharmacology, Toxicology and Pharmaceutics
Alexander K C Leung, Amy A M Leung, Alex H C Wong, Kam L Hon
{"title":"旅行者腹泻:临床回顾。","authors":"Alexander K C Leung, Amy A M Leung, Alex H C Wong, Kam L Hon","doi":"10.2174/1872213X13666190514105054","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Travelers' diarrhea is the most common travel-related malady. It affects millions of international travelers to developing countries annually and can significantly disrupt travel plans.</p><p><strong>Objective: </strong>To provide an update on the evaluation, diagnosis, treatment, and prevention of traveler's diarrhea.</p><p><strong>Methods: </strong>A PubMed search was completed in Clinical Queries using the key term \"traveler's diarrhea\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. Patents were searched using the key term \"traveler's diarrhea\" from www.freepatentsonline.com.</p><p><strong>Results: </strong>Between 10% and 40% of travelers develop diarrhea. The attack rate is highest for travelers from a developed country who visit a developing country. Children are at particular risk. Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces. Most cases are due to a bacterial pathogen, commonly, Escherichia coli, and occur within the first few days after arrival in a foreign country. Dehydration is the most common complication. Pretravel education on hygiene and on the safe selection of food items is important in minimizing episodes. For mild travelers' diarrhea, the use of antibiotic is not recommended. The use of bismuth subsalicylate or loperamide may be considered. For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used. Loperamide may be considered as monotherapy or adjunctive therapy. For severe travelers' diarrhea, antibiotics such as azithromycin, fluoroquinolones, and rifaximin should be used. Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose. Recent patents related to the management of travelers' diarrhea are discussed.</p><p><strong>Conclusion: </strong>Although travelers' diarrhea is usually self-limited, many travelers prefer expedient relief of diarrhea, especially when they are traveling for extended periods by air or ground. Judicious use of an antimotility agent and antimicrobial therapy reduces the duration and severity of diarrhea.</p>","PeriodicalId":20960,"journal":{"name":"Recent patents on inflammation & allergy drug discovery","volume":" ","pages":"38-48"},"PeriodicalIF":4.2000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/1c/RPIAD-13-38.PMC6751351.pdf","citationCount":"0","resultStr":"{\"title\":\"Travelers' Diarrhea: A Clinical Review.\",\"authors\":\"Alexander K C Leung, Amy A M Leung, Alex H C Wong, Kam L Hon\",\"doi\":\"10.2174/1872213X13666190514105054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Travelers' diarrhea is the most common travel-related malady. It affects millions of international travelers to developing countries annually and can significantly disrupt travel plans.</p><p><strong>Objective: </strong>To provide an update on the evaluation, diagnosis, treatment, and prevention of traveler's diarrhea.</p><p><strong>Methods: </strong>A PubMed search was completed in Clinical Queries using the key term \\\"traveler's diarrhea\\\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. Patents were searched using the key term \\\"traveler's diarrhea\\\" from www.freepatentsonline.com.</p><p><strong>Results: </strong>Between 10% and 40% of travelers develop diarrhea. The attack rate is highest for travelers from a developed country who visit a developing country. Children are at particular risk. Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces. Most cases are due to a bacterial pathogen, commonly, Escherichia coli, and occur within the first few days after arrival in a foreign country. Dehydration is the most common complication. Pretravel education on hygiene and on the safe selection of food items is important in minimizing episodes. For mild travelers' diarrhea, the use of antibiotic is not recommended. The use of bismuth subsalicylate or loperamide may be considered. For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used. Loperamide may be considered as monotherapy or adjunctive therapy. For severe travelers' diarrhea, antibiotics such as azithromycin, fluoroquinolones, and rifaximin should be used. Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose. Recent patents related to the management of travelers' diarrhea are discussed.</p><p><strong>Conclusion: </strong>Although travelers' diarrhea is usually self-limited, many travelers prefer expedient relief of diarrhea, especially when they are traveling for extended periods by air or ground. Judicious use of an antimotility agent and antimicrobial therapy reduces the duration and severity of diarrhea.</p>\",\"PeriodicalId\":20960,\"journal\":{\"name\":\"Recent patents on inflammation & allergy drug discovery\",\"volume\":\" \",\"pages\":\"38-48\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/1c/RPIAD-13-38.PMC6751351.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on inflammation & allergy drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1872213X13666190514105054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on inflammation & allergy drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872213X13666190514105054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

背景:旅行者腹泻是最常见的旅行相关疾病。它每年影响数百万前往发展中国家的国际旅行者,会严重扰乱旅行计划:提供有关旅行者腹泻的评估、诊断、治疗和预防的最新信息:方法:使用关键词 "旅行者腹泻 "在PubMed临床查询中进行搜索。搜索策略包括荟萃分析、随机对照试验、临床试验、观察性研究和综述。检索仅限于英文文献。专利检索的关键词为 "旅行者腹泻",网址为 www.freepatentsonline.com.Results:10%到40%的旅行者会患上腹泻。从发达国家前往发展中国家的旅行者发病率最高。儿童的风险尤其高。旅行者腹泻通常是通过摄入被粪便污染的食物和水而引起的。大多数病例是由细菌病原体(通常是大肠杆菌)引起的,发生在抵达外国后的头几天。脱水是最常见的并发症。旅行前关于卫生和安全选择食品的教育对于减少腹泻的发生非常重要。对于轻微的旅行者腹泻,不建议使用抗生素。可考虑使用亚水杨酸铋或洛哌丁胺。对于中度旅行者腹泻,可使用氟喹诺酮类、阿奇霉素和利福昔明等抗生素。洛哌丁胺可作为单一疗法或辅助疗法。对于严重的旅行者腹泻,应使用阿奇霉素、氟喹诺酮类和利福昔明等抗生素。阿奇霉素甚至可用于治疗痢疾,而氟喹诺酮类和利福昔明则不能用于治疗痢疾。本文讨论了与旅行者腹泻治疗相关的最新专利:尽管旅行者腹泻通常是自限性的,但许多旅行者还是希望能尽快缓解腹泻,尤其是在他们长时间乘飞机或地面旅行时。合理使用抗蠕动剂和抗菌治疗可缩短腹泻的持续时间,减轻腹泻的严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Travelers' Diarrhea: A Clinical Review.

Background: Travelers' diarrhea is the most common travel-related malady. It affects millions of international travelers to developing countries annually and can significantly disrupt travel plans.

Objective: To provide an update on the evaluation, diagnosis, treatment, and prevention of traveler's diarrhea.

Methods: A PubMed search was completed in Clinical Queries using the key term "traveler's diarrhea". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. Patents were searched using the key term "traveler's diarrhea" from www.freepatentsonline.com.

Results: Between 10% and 40% of travelers develop diarrhea. The attack rate is highest for travelers from a developed country who visit a developing country. Children are at particular risk. Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces. Most cases are due to a bacterial pathogen, commonly, Escherichia coli, and occur within the first few days after arrival in a foreign country. Dehydration is the most common complication. Pretravel education on hygiene and on the safe selection of food items is important in minimizing episodes. For mild travelers' diarrhea, the use of antibiotic is not recommended. The use of bismuth subsalicylate or loperamide may be considered. For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used. Loperamide may be considered as monotherapy or adjunctive therapy. For severe travelers' diarrhea, antibiotics such as azithromycin, fluoroquinolones, and rifaximin should be used. Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose. Recent patents related to the management of travelers' diarrhea are discussed.

Conclusion: Although travelers' diarrhea is usually self-limited, many travelers prefer expedient relief of diarrhea, especially when they are traveling for extended periods by air or ground. Judicious use of an antimotility agent and antimicrobial therapy reduces the duration and severity of diarrhea.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: Recent Patents on Inflammation & Allergy Drug Discovery publishes review articles by experts on recent patents in the field of inflammation and allergy drug discovery e.g. on novel bioactive compounds, analogs and targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in inflammation and allergy drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信